Barrett N E, Holbrook L, Jones S, Kaiser W J, Moraes L A, Rana R, Sage T, Stanley R G, Tucker K L, Wright B, Gibbins J M
School of Biological Sciences, University of Reading, Whiteknights, Reading, Berkshire, UK.
Br J Pharmacol. 2008 Jul;154(5):918-39. doi: 10.1038/bjp.2008.151. Epub 2008 Apr 21.
Platelets have long been recognized to be of central importance in haemostasis, but their participation in pathological conditions such as thrombosis, atherosclerosis and inflammation is now also well established. The platelet has therefore become a key target in therapies to combat cardiovascular disease. Anti-platelet therapies are used widely, but current approaches lack efficacy in a proportion of patients, and are associated with side effects including problem bleeding. In the last decade, substantial progress has been made in understanding the regulation of platelet function, including the characterization of new ligands, platelet-specific receptors and cell signalling pathways. It is anticipated this progress will impact positively on the future innovations towards more effective and safer anti-platelet agents. In this review, the mechanisms of platelet regulation and current anti-platelet therapies are introduced, and strong, and some more speculative, potential candidate target molecules for future anti-platelet drug development are discussed.
长期以来，血小板在止血过程中的核心重要性已得到公认，而如今其在诸如血栓形成、动脉粥样硬化和炎症等病理状况中的作用也已被充分证实。因此，血小板已成为对抗心血管疾病疗法的关键靶点。抗血小板疗法被广泛应用，但目前的方法在部分患者中缺乏疗效，且伴有包括出血问题在内的副作用。在过去十年中，在理解血小板功能调节方面取得了重大进展，包括鉴定新的配体、血小板特异性受体和细胞信号通路。预计这一进展将对未来开发更有效、更安全的抗血小板药物的创新产生积极影响。在本综述中，介绍了血小板调节机制和当前的抗血小板疗法，并讨论了未来抗血小板药物开发的有力且更具推测性的潜在候选靶分子。
